IP Library Granted Patent US 7,329,646
Granted Patent B2
US 7,329,646 · App. 10/704,409 · Granted Feb 12, 2008

Derivatives of the insulinotropic peptide exendin-4 and methods of production thereof

Assignee: Shanghai Huayi Bio-Lab Co., Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,329,646
App. No.
10/704,409
Granted
Feb 12, 2008
Kind
B2
Abstract

The present invention is directed to the development of novel exendin-4 derivatives exhibiting advantageous glucose-regulatory properties, and to methods of producing these derivatives, including recombinant methods in which these derivatives are produced by cleavage of a fusion protein containing multiple copies of the exendin-4 derivative peptide. The methods of the present invention can be used to simplify the process of producing the disclosed exendin-4 derivatives, thereby lowering the cost of their production.

Claims (7)

1. A peptide comprising an exendin-4 derivative peptide selected from the group consisting of SEQ ID NOs: 3, 6-8.

2. A method for the treatment of a condition involving the dysregulation of insulin levels in a patient in need thereof, said method comprises administering to said patient a therapeutically effective amount of a peptide of claim 1 .

3. A method for the treatment of type II diabetes in a patient in need thereof, said method comprises administering to said patient a therapeutically effective amount of a peptide of claim 1 .

4. The peptide of claim 1 wherein the amino acid residue at position 14 (Xaa 14) of SEQ ID NO:3 is Ile or Leu, and the amino acid residue at position 20 (Xaa 20) of SEQ ID NO:3 is Lys.

5. The peptide of claim 4 wherein Xaa 14 is Ile, and Xaa 20 is Lys.

6. The peptide of claim 1 wherein the amino acid residue at position 14 (Xaa 14) of SEQ ID NO:3 is Ile or Leu, and the amino acid residue at position 20 (Xaa 20) of SEQ ID NO:3 is His.

7. The peptide of claim 6 wherein Xaa 14 is Leu, and Xaa 20 is His.

Assignments (3)
CHANGE OF NAME Recorded Feb 10, 2015
From: SHANGHAI HUYAI BIO-LAB CO., LTD.
To: SHANGHAI BENEMAE PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 034933/0966 →
CHANGE OF NAME AND ADDRESS Recorded Feb 10, 2015
From: SHANGHAI BENEMAE PHARMACEUTICAL COMPANY LIMITED
To: SHANGHAI BENEMAE PHARMACEUTICAL CORPORATION
Reel/Frame 034934/0060 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 7, 2003
From: SUN, YUKUN; WU, DENGXI; CHEN, WEN; ZHU, ZHIYONG
To: SHANGHAI HUYAI BIO-LAB CO., LTD.
Reel/Frame 014689/0946 →
Priority Claims (1)
CN 01 1 12856 · May 10, 2001 · national
Continuity (2)
Continuation In Part PCTCN020031600 · May 8, 2002
Related Publication 20040142866A1 · Jul 22, 2004